A new in vivo pharmacokinetic recall study involving 114 participants in the Estonian Biobank has provided the first clinical confirmation that previously uncharacterized genetic variants in the ...
Proton pump inhibitor therapy is well tolerated at standard doses; even a fivefold increase in the AUC of PPIs appears to cause only negligible side effects. The clinical relevance of these ...
Following the successful completion of the NHS national pilot in April 2025, the highly anticipated first results assessing CYP2C19 genetic testing to guide clopidogrel use in ischaemic stroke and TIA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results